Headquartered in London and New York with offices worldwide, a private equity firm managing ~$65M in assets under management (AUM). The firm invests in both public and private markets across various industries, with a healthcare-focused team dedicated to private market investments. Their average initial check size ranges from $10M to $30M, with follow-on investments expected. The firm has the ability to led, co-lead, or join a round as a syndicate member.
The firm is interested in opportunities in therapeutics, medical devices, and diagnostics. The firm is agnostic to subsectors and indications and is willing to consider orphan drugs. Within therapeutics, they prefer asset-forward companies but are open to platform companies with lead assets or drugs. Regarding the phase of development, the firm seeks clinical stage companies or companies that are no more than 6-9 months away from the clinical stage.
The firm doesn’t have specific requirements for companies’ management teams. The firm will consider board or observer seats on a case-by-case basis, but this is not a requirement.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.







Max Braht, Business Development Manager, Life Science Nation | Diana Caldwell, MBA,CEO and Co-Founder, Amplified Sciences | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Greg Mannix, VP, International Business Development, Life Science Nation | Victoria Costa Paz, CEO and Co-Founder, EYWA Biotech | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Momo Yamamoto, Investor Research Analyst, Life Science Nation | John Qiao, Founder and CEO, RadioClash | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
